X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6903) 6903
Newsletter (136) 136
Newspaper Article (31) 31
Book Chapter (24) 24
Magazine Article (16) 16
Dissertation (15) 15
Conference Proceeding (4) 4
Publication (4) 4
Government Document (2) 2
Streaming Video (2) 2
Book Review (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
zoledronic acid (6682) 6682
humans (3927) 3927
female (2159) 2159
bisphosphonates (2141) 2141
oncology (1962) 1962
male (1761) 1761
osteoporosis (1745) 1745
diphosphonates - therapeutic use (1535) 1535
bone density conservation agents - therapeutic use (1256) 1256
cancer (1197) 1197
aged (1171) 1171
middle aged (1136) 1136
animals (1069) 1069
bone neoplasms - secondary (1061) 1061
metastasis (948) 948
postmenopausal women (945) 945
care and treatment (935) 935
double-blind (909) 909
breast cancer (879) 879
endocrinology & metabolism (869) 869
denosumab (833) 833
bone metastases (811) 811
research (775) 775
bisphosphonate (764) 764
imidazoles - therapeutic use (753) 753
fractures (751) 751
diphosphonates - pharmacology (747) 747
diphosphonates - administration & dosage (746) 746
breast-cancer (741) 741
bone neoplasms - drug therapy (735) 735
diphosphonates - adverse effects (729) 729
risk factors (721) 721
prostate cancer (694) 694
bones (677) 677
alendronate (662) 662
orthopedics (643) 643
bone density conservation agents - adverse effects (627) 627
analysis (624) 624
drug therapy (620) 620
health aspects (597) 597
bone density conservation agents - administration & dosage (593) 593
therapy (590) 590
treatment outcome (589) 589
medicine & public health (576) 576
pamidronate (574) 574
bone-mineral density (569) 569
aged, 80 and over (562) 562
adult (559) 559
bone (548) 548
prevention (523) 523
pharmacology & pharmacy (521) 521
imidazoles - pharmacology (490) 490
osteonecrosis (484) 484
osteoporosis - drug therapy (483) 483
breast neoplasms - pathology (482) 482
in-vitro (482) 482
metastases (481) 481
imidazoles - administration & dosage (479) 479
multiple-myeloma (473) 473
prostate-cancer (465) 465
breast neoplasms - drug therapy (458) 458
chemotherapy (455) 455
women (453) 453
skeletal complications (434) 434
bone density - drug effects (432) 432
skeletal-related events (424) 424
bone density conservation agents - pharmacology (423) 423
mice (413) 413
apoptosis (411) 411
phosphonates (411) 411
diphosphonates (409) 409
risk (401) 401
surgery (396) 396
bone metastasis (383) 383
survival (379) 379
antineoplastic agents - therapeutic use (374) 374
prostatic neoplasms - pathology (365) 365
medicine, general & internal (363) 363
bone density (360) 360
rheumatology (356) 356
imidazoles - adverse effects (349) 349
multiple myeloma (343) 343
bone mineral density (342) 342
cell line, tumor (335) 335
clinical trials (334) 334
dentistry, oral surgery & medicine (332) 332
dentistry (327) 327
prostatic neoplasms - drug therapy (319) 319
patients (317) 317
density (312) 312
risk-factors (307) 307
postmenopausal osteoporosis (305) 305
randomized-trial (305) 305
pain (304) 304
complications and side effects (303) 303
disease (303) 303
retrospective studies (303) 303
bone cancer (302) 302
quality of life (302) 302
urology & nephrology (298) 298
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6848) 6848
German (85) 85
Spanish (62) 62
French (55) 55
Japanese (29) 29
Portuguese (23) 23
Chinese (21) 21
Russian (14) 14
Turkish (14) 14
Polish (10) 10
Hungarian (6) 6
Italian (4) 4
Korean (4) 4
Czech (2) 2
Arabic (1) 1
Croatian (1) 1
Dutch (1) 1
Estonian (1) 1
Persian (1) 1
Slovenian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9757, pp. 1989 - 1999
Summary Background Bisphosphonates reduce the risk of skeletal events in patients with malignant bone disease, and zoledronic acid has shown potential anticancer effects in preclinical and clinical studies... 
Internal Medicine | LONG-TERM | SURVIVAL | JAW | MEDICINE, GENERAL & INTERNAL | BISPHOSPHONATES | PAMIDRONATE | THERAPY | DOUBLE-BLIND | EARLY BREAST-CANCER | OSTEONECROSIS | PREVENTIVE MEASURES | Humans | Middle Aged | Multiple Myeloma - secondary | Bone Neoplasms - secondary | Imidazoles - administration & dosage | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Multiple Myeloma - drug therapy | Diphosphonates - therapeutic use | Adult | Female | Imidazoles - therapeutic use | Odds Ratio | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Bone Density Conservation Agents - therapeutic use | Logistic Models | Treatment Outcome | United Kingdom | Diphosphonates - administration & dosage | Bone Density Conservation Agents - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bone Neoplasms - prevention & control | Clodronic Acid - therapeutic use | Aged | Clodronic Acid - administration & dosage | Infusions, Intravenous | Neoplasm Staging | Research Design | Zoledronic acid | Complications and side effects | Dosage and administration | Drug therapy | Patient outcomes | Multiple myeloma | Medical research | Chemotherapy | Radiation therapy | Medical treatment | Cancer
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2011, Volume 365, Issue 15, pp. 1396 - 1405
Journal Article
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10024, pp. 1163 - 1177
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2009, Volume 360, Issue 7, pp. 679 - 691
This large trial tested the effect of adding zoledronic acid to adjuvant endocrine treatment... 
BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS | MEDICINE, GENERAL & INTERNAL | BONE LOSS | SOLID TUMORS | TAMOXIFEN | METASTASES | DELTA T-CELLS | RECEPTOR | ADJUVANT THERAPY | POSTMENOPAUSAL WOMEN | AUSTRIAN BREAST | Breast Neoplasms - surgery | Triazoles - adverse effects | Follow-Up Studies | Humans | Middle Aged | Receptors, Estrogen - analysis | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Diphosphonates - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Imidazoles - therapeutic use | Drug Therapy, Combination | Goserelin - therapeutic use | Aromatase Inhibitors - therapeutic use | Diphosphonates - adverse effects | Triazoles - therapeutic use | Bone Density Conservation Agents - adverse effects | Premenopause | Imidazoles - adverse effects | Bone Density Conservation Agents - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Estrogen Antagonists - therapeutic use | Tamoxifen - therapeutic use | Estrogen Antagonists - adverse effects | Tamoxifen - adverse effects | Nitriles - adverse effects | Nitriles - therapeutic use | Zoledronic acid | Care and treatment | Usage | Breast cancer | Health aspects | Function tests (Medicine) | Chemotherapy | Acids | Womens health | Menopause | Colorectal cancer | Cytotoxicity | Radiation therapy | Cancer therapies | Index Medicus | Abridged Index Medicus
Journal Article
Journal of controlled release, ISSN 0168-3659, 2015, Volume 210, pp. 198 - 207
Combinations of topoisomerase inhibitors I and II have been found to synergistically inhibit cancer cell growth in vitro, yet clinical studies of these types... 
Synergistic | Chemotherapy | Drug combinations | Polymer drug conjugate | SINGLE-AGENT CHEMOTHERAPY | CHEMISTRY, MULTIDISCIPLINARY | OVARIAN-CARCINOMA | CELL LUNG-CANCER | HUMAN BREAST-CARCINOMA | ZOLEDRONIC ACID | PHASE-I TRIAL | ENDOTHELIAL-CELLS | IRINOTECAN | PHARMACOLOGY & PHARMACY | PEGYLATED-LIPOSOMAL DOXORUBICIN | CYTOTOXIC AGENTS | Hyaluronic Acid - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Camptothecin - chemistry | Apoptosis - drug effects | Humans | Hyaluronic Acid - chemistry | Topoisomerase I Inhibitors - administration & dosage | Antineoplastic Agents, Phytogenic - chemistry | Topoisomerase II Inhibitors - administration & dosage | Doxorubicin - chemistry | Neoplasms - drug therapy | Drug Synergism | Antineoplastic Agents, Phytogenic - administration & dosage | Animals | Topoisomerase II Inhibitors - chemistry | Tumor Burden - drug effects | Cell Line, Tumor | Camptothecin - administration & dosage | Female | Mice, Inbred BALB C | Neoplasms - pathology | Topoisomerase I Inhibitors - chemistry | Doxorubicin - administration & dosage | Hyaluronic acid | Anthracyclines | Analysis | Medical research | Medicine, Experimental | Drug therapy, Combination | Polymers | Index Medicus | synergistic | polymer drug conjugate | chemotherapy | drug combinations
Journal Article
Osteoporosis international, ISSN 1433-2965, 2018, Volume 29, Issue 5, pp. 1155 - 1163
Annual intravenous administration of zoledronic acid is used in the treatment of osteoporosis... 
Osteoporosis | Modeling and simulation | Tartrate-resistant acid phosphatase 5b (TRACP-5b) | Medicine & Public Health | Orthopedics | Bone resorption marker | Rheumatology | Zoledronic acid | Bone mineral density | Endocrinology | HOMEOSTASIS | DENOSUMAB | PREVENTION | PHARMACODYNAMICS | TERIPARATIDE | TRIAL | THERAPY | ENDOCRINOLOGY & METABOLISM | BMD | POSTMENOPAUSAL WOMEN | Bone Resorption - diagnosis | Bone Resorption - physiopathology | Zoledronic Acid - pharmacology | Double-Blind Method | Drug Administration Schedule | Zoledronic Acid - therapeutic use | Tartrate-Resistant Acid Phosphatase - blood | Humans | Bone Resorption - drug therapy | Bone Density Conservation Agents - therapeutic use | Male | Osteoporosis - drug therapy | Biomarkers - blood | Bone Density Conservation Agents - administration & dosage | Zoledronic Acid - administration & dosage | Bone Density Conservation Agents - pharmacology | Bone Density - drug effects | Models, Biological | Aged, 80 and over | Female | Aged | Infusions, Intravenous | Osteoporosis - physiopathology | Lumbar Vertebrae - physiopathology | Bone resorption | Physiological aspects | Development and progression | Bones | Models | Drug therapy | Acid phosphatase | Health aspects | Density | Intravenous administration | Spine (lumbar) | Phosphatase | Patients | Fractures | Acids | Mathematical models | Acid phosphatase (tartrate-resistant) | Bone density | Original
Journal Article
Bone, ISSN 8756-3282, 2014, Volume 66, Issue 100, pp. 240 - 250
Journal Article